Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Sarah Frey; Teresa Po Yu Chiang; Caoilfhionn M. Connolly; Mayan Teles; Jennifer L. Alejo; Brian J. Boyarsky; Lisa Christopher-Stine; William A. Werbel; Allan B. Massie; Dorry L. Segev; Julie J. Paik

doi:10.1016/S2665-9913(21)00417-3

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Sarah Frey, Teresa Po Yu Chiang, Caoilfhionn M. Connolly, Mayan Teles, Jennifer L. Alejo, Brian J. Boyarsky, Lisa Christopher-Stine, William A. Werbel, Allan B. Massie, Dorry L. Segev, Julie J. Paik

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	e241-e243
Journal	The Lancet Rheumatology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/S2665-9913(21)00417-3
State	Published - Apr 2022

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.1016/S2665-9913(21)00417-3

Cite this

Frey, S., Chiang, T. P. Y., Connolly, C. M., Teles, M., Alejo, J. L., Boyarsky, B. J., Christopher-Stine, L., Werbel, W. A., Massie, A. B., Segev, D. L., & Paik, J. J. (2022). Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. The Lancet Rheumatology, 4(4), e241-e243. https://doi.org/10.1016/S2665-9913(21)00417-3

Frey, S, Chiang, TPY, Connolly, CM, Teles, M, Alejo, JL, Boyarsky, BJ, Christopher-Stine, L , Werbel, WA, Massie, AB, Segev, DL & Paik, JJ 2022, 'Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease', The Lancet Rheumatology, vol. 4, no. 4, pp. e241-e243. https://doi.org/10.1016/S2665-9913(21)00417-3

@article{c5685633b35840bfbe03771374cf30d2,

title = "Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease",

author = "Sarah Frey and Chiang, {Teresa Po Yu} and Connolly, {Caoilfhionn M.} and Mayan Teles and Alejo, {Jennifer L.} and Boyarsky, {Brian J.} and Lisa Christopher-Stine and Werbel, {William A.} and Massie, {Allan B.} and Segev, {Dorry L.} and Paik, {Julie J.}",

note = "Funding Information: DLS reports consulting from CSL Behring, Novartis, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific; and speaking honoraria from Sanofi and Novartis. LC-S reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, Serono, ArgenX, Allogene, Roivant, and Octapharm; royalties for intellectual property related to anti-HMGCR assay from Inova Diagnostics; grants from Pfizer, Corbus, and Kezar; payment for expert testimony from Bendin Sumrall and Ladner, Feldman, Kleidman Coffey & Sappe, Downs Ward Bender Hauptmann & Herzog, and Sulloway and Hollis. All other authors declare no competing interests. SF and TP-YC contributed equally. DLS and JJP were co-senior authors. This work was made possible by the generous support of the Ben Dov family. This work was supported by grant number F32DK124941 to BJB, T32DK007713 from the National Institute of Diabetes and Digestive and Kidney Diseases to JLA, K24AI144954 to DLS, U01AI138897 and K23AI157893 from National Institute of Allergy and Infectious Diseases to WAW, and K23AR073927 from National Institute of Arthritis and Musculoskeletal and Skin Diseases to JJP. The analyses described in this Comment are the responsibility of the authors alone and do not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government. ",

year = "2022",

month = apr,

doi = "10.1016/S2665-9913(21)00417-3",

language = "English (US)",

volume = "4",

pages = "e241--e243",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

AU - Frey, Sarah

AU - Chiang, Teresa Po Yu

AU - Connolly, Caoilfhionn M.

AU - Teles, Mayan

AU - Alejo, Jennifer L.

AU - Boyarsky, Brian J.

AU - Christopher-Stine, Lisa

AU - Werbel, William A.

AU - Massie, Allan B.

AU - Segev, Dorry L.

AU - Paik, Julie J.

N1 - Funding Information: DLS reports consulting from CSL Behring, Novartis, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific; and speaking honoraria from Sanofi and Novartis. LC-S reports consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, Serono, ArgenX, Allogene, Roivant, and Octapharm; royalties for intellectual property related to anti-HMGCR assay from Inova Diagnostics; grants from Pfizer, Corbus, and Kezar; payment for expert testimony from Bendin Sumrall and Ladner, Feldman, Kleidman Coffey & Sappe, Downs Ward Bender Hauptmann & Herzog, and Sulloway and Hollis. All other authors declare no competing interests. SF and TP-YC contributed equally. DLS and JJP were co-senior authors. This work was made possible by the generous support of the Ben Dov family. This work was supported by grant number F32DK124941 to BJB, T32DK007713 from the National Institute of Diabetes and Digestive and Kidney Diseases to JLA, K24AI144954 to DLS, U01AI138897 and K23AI157893 from National Institute of Allergy and Infectious Diseases to WAW, and K23AR073927 from National Institute of Arthritis and Musculoskeletal and Skin Diseases to JJP. The analyses described in this Comment are the responsibility of the authors alone and do not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85124010427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124010427&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(21)00417-3

DO - 10.1016/S2665-9913(21)00417-3

M3 - Comment/debate

C2 - 35072108

AN - SCOPUS:85124010427

SN - 2665-9913

VL - 4

SP - e241-e243

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 4

ER -

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this